8-K: Bio-Techne Reports Mixed Q2 Results Amidst Macroeconomic Headwinds, Declares Dividend

Bio-Techne's second quarter fiscal 2024 results show a slight revenue decrease and a drop in earnings per share, while the company also announced a cash dividend of $0.08 per share.

Summary

• Bio-Techne reported its second quarter fiscal year 2024 results, with revenue remaining flat at $272.6 million.
• Organic revenue declined by 2%, but this was offset by a 1% contribution from acquisitions and a 1% favorable impact from foreign currency exchange.
• GAAP earnings per share (EPS) decreased to $0.17, down from $0.31 in the same quarter last year.
• Adjusted EPS also decreased to $0.40, compared to $0.47 in the prior year.
• The company experienced a challenging macroeconomic environment, particularly in the BioPharma sector, but saw strength in the academic end market with high single-digit growth.
• Cash flow from operations increased by 18% to $142.5 million.
• The company declared a cash dividend of $0.08 per share, payable on February 26, 2024, to shareholders of record on February 12, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While there are positives like cash flow growth and strength in certain segments, the overall decline in revenue and earnings is concerning. The company is facing macroeconomic headwinds and challenges in China, which adds to the uncertainty.

Positives

• Cash flow generated from operations increased by 18% to $142.5 million.
• The company saw 20% growth in instrument consumables.
• The academic end market showed high single-digit growth.
• The Diagnostics and Genomics segment experienced an 11% increase in net sales.
• Bio-Techne declared a cash dividend of $0.08 per share.

Negatives

• Second quarter organic revenue declined by 2%.
• GAAP earnings per share (EPS) decreased to $0.17 from $0.31 in the prior year.
• Adjusted EPS decreased to $0.40 from $0.47 in the same quarter last year.
• The Protein Sciences segment experienced a 3% decrease in net sales.
• GAAP operating income decreased 44% to $38.0 million.
• Adjusted operating income decreased 15% compared to the second quarter of fiscal 2023.
• The company faced increased headwinds from BioPharma macroeconomic conditions.

Risks

• The company is facing challenges from the BioPharma macroeconomic environment.
• There is conservatism from a subset of biotech customers.
• The company is navigating a challenging landscape in China.
• The company's results are subject to currency exchange rate fluctuations.
• The company's results are subject to the costs and results of research and product development efforts.

Future Outlook

The company is seeing initial signs of stabilization in China and remains confident in the long-term high-growth potential of this geography. The company believes its unique life science tools and diagnostics portfolio, financial strength, experienced team, and deep scientific capabilities position it to create value for all stakeholders going forward.

Management Comments

• Kim Kelderman, President and Chief Executive Officer, stated he is pleased with the team's continued execution in a dynamic operating environment.
• Kelderman noted the company navigated a challenging China landscape and conservatism from some biotech customers, which was partially offset by strength in the academic end market.
• Kelderman expressed confidence in the long-term high-growth potential of China.
• Kelderman thanked Chuck Kummeth for his support during the transition prior to his retirement on July 1, 2024.
• Kelderman stated he is excited to lead the team through the next phase of growth.

Industry Context

The results reflect the broader challenges faced by the life sciences industry, particularly in the BioPharma sector, due to macroeconomic conditions. However, Bio-Techne's growth in instrument consumables and the academic market suggests a resilience in certain segments. The company's focus on providing highly productive analytical tools is a key differentiator in a competitive market.

Comparison to Industry Standards

• Bio-Techne's performance is mixed when compared to industry peers. Companies like Danaher and Thermo Fisher Scientific, which also operate in the life sciences tools and diagnostics space, have shown varying results in recent quarters, with some experiencing similar headwinds in the biopharma sector.
• While Bio-Techne's organic revenue decline of 2% is concerning, the 20% growth in instrument consumables is a positive sign, indicating strong demand for their analytical tools, which is a key area of focus for many life science companies.
• The decrease in GAAP EPS and adjusted EPS is a common trend among companies facing macroeconomic pressures, but the magnitude of the decrease for Bio-Techne is significant and warrants attention.
• The 18% increase in cash flow from operations is a positive indicator of the company's operational efficiency and financial health, which is a key metric that investors often compare across companies in the sector.
• The company's performance in the academic market, with high single-digit growth, is a positive sign, as this segment is often less volatile than the biopharma sector. This is a key area of focus for companies like Agilent and PerkinElmer.
• The Diagnostics and Genomics segment's 11% growth is a positive sign, but the decrease in operating margin due to the Lunaphore acquisition is a concern that needs to be monitored.

Management Changes

Stakeholder Impact

• Shareholders will receive a cash dividend of $0.08 per share.
• Employees may be impacted by restructuring and cost-cutting measures.
• Customers will benefit from the company's focus on providing highly productive analytical tools.
• Suppliers may be affected by changes in the company's supply chain.
• Creditors may be impacted by the company's financial performance.

Next Steps

• The company will host an earnings conference call on February 1, 2024, to discuss the results.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Keywords

Bio-Techne, biotechnology, life sciences, diagnostics, genomics, protein sciences, revenue, earnings, EPS, dividend, organic growth, macroeconomic, instrument consumables, academic market